FDA Announces Public Meeting to Discuss Reauthorization of Prescription Drug User Fee Act

Summary

The FDA is holding a public meeting to gather public comments on proposed recommendations for reauthorizing the Prescription Drug User Fee Act (PDUFA) for fiscal years 2018 through 2022, with the goal of ensuring the continued review of human drug applications and the collection of prescription drug user fees.